Kangpu Biopharmaceuticals, a clinical-stage company based in Shanghai, China, announced that the Company has completed patient enrollment for the Phase IIa clinical trial of KPG-818 aimed at the treatment of systemic lupus erythematosus in the US.
Kangpu Biopharmaceuticals, a clinical-stage company based in Shanghai, China, announced that the Company has completed patient enrollment for the Phase IIa clinical trial of KPG-818 aimed at the treatment of systemic lupus erythematosus in the US.